Amylyx Pharmaceuticals Etf Performance
| AMLX Etf | USD 4.05 0.09 2.27% |
The etf shows a Beta (market volatility) of 2.03, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Amylyx Pharmaceuticals will likely underperform.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Amylyx Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating essential indicators, Amylyx Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 8709 shares by Gina Mazzariello of Amylyx Pharmaceuticals at 3.1967 subject to Rule 16b-3 | 09/30/2024 |
2 | Amylyx Co-CEO sells over 59,000 in company stock | 10/02/2024 |
3 | Amylyx Pharmaceuticals, Inc. Short Interest Down 21.1 percent in October | 10/28/2024 |
4 | Theres No Escaping Amylyx Pharmaceuticals, Inc.s Muted Revenues Despite A 81 percent Share Price Rise | 11/04/2024 |
5 | Acquisition by Justin Klee of 63690 shares of Amylyx Pharmaceuticals at 1.57 subject to Rule 16b-3 | 11/06/2024 |
6 | Amylyx Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/08/2024 |
7 | Crude Oil Rises Sharply US Homebuilder Sentiment Surges In November | 11/18/2024 |
8 | Baird R W Upgrades Amylyx Pharmaceuticals to Strong-Buy - MarketBeat | 11/19/2024 |
9 | Disposition of 5421 shares by Bedrosian Camille L of Amylyx Pharmaceuticals at 5.5354 subject to Rule 16b-3 | 12/02/2024 |
10 | Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist in Post-Bariatric Hypoglycemia | 12/04/2024 |
11 | Is Amylyx Pharmaceuticals In A Good Position To Invest In Growth | 12/10/2024 |
12 | Little Excitement Around Amylyx Pharmaceuticals, Inc.s Revenues As Shares Take 26 percent Pounding | 12/19/2024 |
| Begin Period Cash Flow | 63.2 M | |
| Free Cash Flow | 10.7 M |
Amylyx |
Amylyx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 301.00 in Amylyx Pharmaceuticals on September 24, 2024 and sell it today you would earn a total of 104.00 from holding Amylyx Pharmaceuticals or generate 34.55% return on investment over 90 days. Amylyx Pharmaceuticals is currently generating 0.6194% in daily expected returns and assumes 5.6674% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of etfs are less volatile than Amylyx, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amylyx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amylyx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as Amylyx Pharmaceuticals, and traders can use it to determine the average amount a Amylyx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1093
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AMLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.67 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Amylyx Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amylyx Pharmaceuticals by adding it to a well-diversified portfolio.
Amylyx Pharmaceuticals Fundamentals Growth
Amylyx Etf prices reflect investors' perceptions of the future prospects and financial health of Amylyx Pharmaceuticals, and Amylyx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amylyx Etf performance.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (181.88) % | ||||
| Current Valuation | 45.11 M | ||||
| Shares Outstanding | 68.55 M | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 1.41 X | ||||
| Revenue | 380.79 M | ||||
| EBITDA | 39.89 M | ||||
| Cash And Equivalents | 206.68 M | ||||
| Cash Per Share | 3.53 X | ||||
| Total Debt | 4.24 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 2.86 X | ||||
| Cash Flow From Operations | 11.92 M | ||||
| Earnings Per Share | (3.82) X | ||||
| Total Asset | 517.45 M | ||||
| Retained Earnings | (304.95 M) | ||||
About Amylyx Pharmaceuticals Performance
Evaluating Amylyx Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Amylyx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amylyx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.| Amylyx Pharmaceuticals is way too risky over 90 days horizon | |
| Amylyx Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Little Excitement Around Amylyx Pharmaceuticals, Inc.s Revenues As Shares Take 26 percent Pounding |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.